Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease.
Summary
This mechanistic study identifies glycoRNAs in human liver and shows they are reduced in MASLD. Loss is linked to downregulation of SIDT1 and DTWD2; restoring these factors in vivo attenuated MASH in mice, positioning glycoRNA biogenesis as a therapeutic lever and potential biomarker source.
Key Findings
- GlycoRNAs are synthesized in human liver tissue, primary hepatocytes, and hepatic tumor cells and are reduced in MASLD.
- Reduced SIDT1 and DTWD2 expression drives glycoRNA loss; inhibiting these increased fatty acid load and macrophage-evoked inflammation in human hepatocytes.
- AAV-mediated restoration of SIDT1/DTWD2 in vivo attenuated MASH in mice.
- Eight glycoRNAs downregulated in steatotic human liver/hepatocytes were identified, supporting biomarker potential.
Clinical Implications
GlycoRNA species and their biosynthetic mediators (SIDT1, DTWD2) could serve as biomarkers of liver injury and as targets for interventions aimed at halting or reversing MASH progression.
Why It Matters
First liver-focused report linking impaired glycoRNA biogenesis to MASLD with in vivo rescue of MASH, suggesting a new RNA modality for diagnostics and therapy.
Limitations
- Human clinical causality and longitudinal prognostic value of glycoRNAs remain unproven
- Scope limited to selected biosynthetic mediators and a subset of glycoRNA species
Future Directions
Define the glycoRNA landscape across MASLD stages, develop minimally invasive assays, and test SIDT1/DTWD2-targeted interventions in large-animal models and early-phase trials.
Study Information
- Study Type
- Basic/mechanistic research
- Research Domain
- Pathophysiology
- Evidence Level
- V - Preclinical mechanistic evidence in human tissues and mouse models
- Study Design
- OTHER